The projected revenue growth for Amicus Therapeutics, especially from its key product Galafold, indicates a positive outlook for the company's financial health and market performance. This growth forecast is likely to be viewed favorably by investors, potentially leading to an increase in stock price in the short term. The specific mention of Galafold's expected revenue growth highlights its significance to the company's overall financial strategy and success.